Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab

CONCLUSIONS: Most of mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells. This finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.PMID:34084279 | PMC:PMC8169066 | DOI:10.18632/oncotarget.27965
Source: Oncotarget - Category: Cancer & Oncology Authors: Source Type: research